<DOC>
	<DOC>NCT01059864</DOC>
	<brief_summary>All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.</brief_summary>
	<brief_title>Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>must be diagnosed as having active rheumatoid arthritis agree to participate in the study and sign and informed consent document History of serious infection within the past 6 months test positive for TB have any uncontrolled clinically significant disease or laboratory tests require administration of prohibited medications during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>lipids</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
</DOC>